Clinical Trials · NCT01491971
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 76
- Start date
- Jan 2012
- Locations
- 15 sites, United States, Canada
- Primary endpoint
- Plasma degarelix PK profile (blood sample analysis): measured by (Cmax, AUC, Tmax)